File photo (Endpoints News)
In a stinging setback, Pfizer’s cancer blockbuster Ibrance flops in key adjuvant setting
One of Pfizer’s top, long-running R&D catalysts has gone up in smoke, and it took an $11 billion bite of their market cap in the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
